L model of Maroteaux-Lamy syndrome (or Mucopolysaccharidosis VI)Paola Saccone1,2*, Gabriella Cotugno1,3*, Fabio Russo1, Rosa Mastrogiacomo1, Alessandra Tessitore1, Alberto Auricchio1,three Elvira De Leonibus1,1Received 30 July 2013 Accepted 9 December 2013 Published 10 JanuaryTelethon Institute of Genetics and Medicine (TIGEM), Naples, Italy, 2Institute of Genetics and Biophysics, CNR, Naples, Italy, Medical Genetics, Dept. of Pediatrics, “Federico II” University, Naples, Italy.Correspondence and requests for materials ought to be addressed to E.D.L. (deleonibus@ igb.cnr.it)Maroteaux-Lamy illness, also referred to as mucopolysaccharidosis (MPS) VI, is definitely an MPS disorder caused by mutations inside the ARSB gene encoding for the lysosomal enzyme arysulfatase B (ARSB). Deficient ARSB activity leads to lysosomal accumulation of dermatan sulfate in a wide array of tissues and organs.Niacin You will discover different animal models of MPS VI that have been nicely characterized from a biochemical and morphological point of view. In this study, we report the sensory-motor characterization of MPS VI rats carrying homozygous null ARSB mutations. We show that adult MPS VI rats are especially impaired in vertical activity and motor endurance. All together, these information are constant with biochemical findings that show a major impairment in connective tissues, which include joints and bones. The behavioral abnormalities of MPS VI rats represent basic endpoints for research aimed at testing the pre-clinical safety and efficacy of novel therapeutic approaches for MPS VI.ucopolysaccharidoses (MPS) are a group of lysosomal storage problems caused by deficiency of enzymes which are accountable for catalyzing the degradation of glycosaminoglycans (GAGs). MPS VI, also called Maroteaux-Lamy illness, is amongst the MPS problems with autosomal recessive inheritance and is triggered by mutations in the ARSB gene encoding for the lysosomal enzyme arysulfatase B (ARSB).Olacaftor ARSB mutations result in defective ARSB activity which leads to lysosomal accumulation of dermatan sulfate and chondroitin sulfate in a wide range of tissues and organs. Simply because the extent and timing on the damage in distinctive tissues is variable, as will be the case with all MPS issues, MPS VI can be a clinically heterogeneous disease when it comes to the extent and rate of progression of organ impairment1. Regardless of such heterogeneity, classic features of MPS VI patients involve dwarfism/growth retardation, progressive skeletal (dystosis multiplex) and joint deformities, upper airway obstruction, aortal and mitral valvular dysfunction, spinal cord compression, hepatomegaly, and corneal clouding1. As a consequence, if not treated, MPS VI sufferers might in the end grow to be wheelchair-bound or bedridden on account of skeletal, joint and cardiopulmonary defects.PMID:23614016 As opposed to most other MPS disorders, which include MPS I, II, III and multiple sulfatase deficiency (MSD), neurodegeneration and also the linked cognitive impairment is commonly absent in MPS VI sufferers. Mental retardation has been seldom reported2 and is usually related with meningeal thickening and hydrocephalus2,3. Thus, cognitive impairment will not be prominent in MPS VI pathology. Though, bone marrow transplantation and enzyme replacement therapy (ERT) clearly ameliorate the clinical phenotype of MPS VI patients4, there is certainly no remedy for MPS VI or any other MPS. Preclinical simple research on spontaneous animal models of MPS VI in cats, dogs, and rats, as well as a knockout model in mice developed w.
Posted inUncategorized